undamentalytics Newsletter

Ring Christine: insider trades

Officer at Nurix Therapeutics, Inc. No open-market purchases and 13 sales not made under a pre-set plan, reported from August 2, 2022 to July 30, 2026.

What happened after Ring Christine’s sales?

After their sales, the shares moved +7.9% against the index over 12 months on average (a negative figure means selling was the right call); 56% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Ring Christine: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 13 +4.4% −4.5% 54% 5 −0.43 0.69 No reliable evidence
Sales, 12 months after the report 9 +7.9% −30.4% 56% 4 0.43 0.69 No reliable evidence
Sales, 12 months after the trade 10 +17.3% −3.1% 50% 4 0.63 0.57 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Nurix Therapeutics, Inc. NRIX Chief Legal Officer013August 2, 2022July 30, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
July 30, 2026July 30, 2026 NRIX Sale $89,943 +13.6%not yetnot yet
April 30, 2026April 30, 2026 NRIX Sale $53,513 +32.7%not yetnot yet
January 30, 2026January 30, 2026 NRIX Sale $73,370 −4.5%not yetnot yet
October 30, 2025October 30, 2025 NRIX Sale $46,643 +28.4%not yet+88.6%
July 30, 2025July 30, 2025 NRIX Sale $46,130 −5.1%+85.0%+76.3%
April 30, 2025April 30, 2025 NRIX Sale $33,281 −12.7%+21.7%+14.3%
January 30, 2025January 30, 2025 NRIX Sale $63,940 −37.3%−30.7%−30.9%
October 30, 2024October 30, 2024 NRIX Sale $101,664 −30.6%−70.3%−66.8%
July 30, 2024July 30, 2024 NRIX Sale $60,356 +9.2%−64.5%−63.0%
April 30, 2024April 30, 2024 NRIX Sale $18,217 +55.3%−30.4%−20.6%
January 30, 2024January 30, 2024 NRIX Sale $14,062 +61.6%+114.5%+122.5%
August 1, 2023July 31, 2023 NRIX Sale $13,703 −33.4%+102.2%+103.3%
August 2, 2022August 1, 2022 NRIX Sale $11,157 −20.4%−56.4%−50.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Ring Christine traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.